STOP Heart Disease in Breast Cancer Survivors Trial

• Status: Terminated
• Trial end date: 2018-05-25
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment. Atorvastatin may reduce or eliminate the harmful effects of chemotherapy treatment to the heart tissue of breast cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cedars-Sinai Medical Center
• Collaborator: California Breast Cancer Research Program
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Female patients with newly diagnosed stage 1-3 breast cancer

• Histologically confirmed HER2, ER, and PR status

• Recommended to undergo trastuzumab treatment, with or without anthracycline. Patients will be eligible for up to 3 weeks after starting treatment.

• Age minimum 18 years

• Able and willing to read, understand, and sign an informed consent form (ICF) and medical release form

• Willing and able to comply with trial protocol and follow-up

• ECOG performance status 0-1 (Karnofsky ≥ 70%)

Exclusion Criteria:

• Prior use of statin medication within the past year

• Not using statin medication but is eligible for statin therapy based on the 2013 ACC/AHA guidelines (LDL cholesterol >190, or LDL <190 and ASCVD risk >7.5%; http://tools.acc.org/ASCVD-Risk-Estimator/) and is > 50 years old; or is eligible for statin therapy based on the 2013 ACC/AHA guidelines and is 40-50 years old and wishes to be placed on statin therapy

• History of adverse effects, intolerance, or allergic reactions attributed to statin medication

• Current use of gemfibrozil, cyclosporine, clarithromycin, itraconazole, erythromycin, the hepatitis C protease inhibitor telaprevir, HIV protease inhibitors, colchicine, or red yeast rice

• Current use of any other investigational agent

• Pregnant or intention to get pregnant during the next 18 months. Pregnant women are excluded from this study because atorvastatin is a lipid-lowering agent with the potential for teratogenic or abortifacient effects, and MRI is contraindicated in pregnant women.

• History of diabetes, severe lung disease, renal disease (creatinine > 1.8 mg/dL or CrCl ≤ 50 mL/min), or hepatic disease (AST and ALT > 3 times upper normal limits)

• Abnormal baseline echocardiogram or cardiac MRI (detection of congenital heart disease; ischemic heart disease; moderate or severe valvular heart disease; cardiomyopathy; EF < 55%)

• Previously known or diagnosed heart disease (e.g. congenital; valvular; coronary artery disease; history of myocardial infarction or acute coronary syndrome; cardiomyopathy, including infiltrative, hypertensive, hypertrophic, dilated, constrictive pericarditis, or other cardiomyopathy)

• Left ventricular dysfunction (EF < 55%)

• Prior non-cardiac illness with an estimated life expectancy < 4 years

• Known active infection with HIV

• Allergy or contraindication to MRI testing, including claustrophobia, metallic parts in body the prohibiting MRI, prior gadolinium contrast reaction, or uncontrolled moderate hypertension (sitting blood pressure >160/95 mm Hg with measurements recorded on at least 2 occasions).

• Has metallic breast expanders in place at the time of screening

• Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data